ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BLTE
RYTM (38) LGND (62) MANE (55) GRFS (54) ⌘ Pro Terminal →

Belite Bio Inc (BLTE) — RQD Stock Rating Cockpit

$153.67 -0.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $153.19

Belite Bio Inc (BLTE) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $6.23B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BLTE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BLTE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Belite Bio Inc (NASDAQ: BLTE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $153.67 (-0.69% 1D, market cap $6.23B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BLTE ranks #556 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BLTE compare to RYTM and LGND in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLTE carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.9%. By comparison, RYTM (Rhythm Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.6%, cap $6.37B) and LGND (Ligand Pharmaceuticals Incorporated) posts a C grade (62/100 RQD, P/E 50.8x, ROIC 3.0%, cap $6.43B). Among the 5-stock peer group, LGND leads on earnings multiple (50.8x) while LGND leads on capital efficiency (3.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BLTE?
▼

Per BLTE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001889109), Belite Bio Inc generated $235.8M in revenue (+110.5% YoY), -$77.6M in net income, and -$37.1M in free cash flow against $780.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $153.19 (-0.31%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (9)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$210 Bull$138 Base$108 Bear
📬 FREE BLTE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BLTE)Realized 20D OHLCV Swing Band: ±8.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY BLTE SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (25% of score)

20D Institutional Volume Accumulation (±8.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$158.59-7.1% Next Q
Q2 (-2Q)
41
Grade D$147.34-2.7% Next Q
Q3 (-1Q)
39
Grade E$143.35+7.2% Next Q
Current
36
Grade D-$153.67-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BLTE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BLTE currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($161.35) and Max Pain ($161.35) forces dealer call-delta covering toward $210.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BLTE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BLTE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
50.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE53% OF RANGE
L: $102$153.67H: $200
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on BLTE

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-15.9% ROIC with 42.0% gross margin and -0.61% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

12/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like BLTE
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BLTE)

  • ✓Walkthrough of BLTE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BLTE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.54%📐 HORIZONTAL RANGE
2026-11-03O $150.3H $154.7L $150.3C $153.7VOL 234.9K
RES: $225.2SUP: $138.8SMA50: $161.4SMA200: $160.4
$203.7$182.5$161.4$140.2$119.1RES $225.2SUP $138.8$153.72026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BLTE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BLTE Butterfly Map → + Track BLTE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +110.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BLTE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BLTE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BLTE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BLTE)

Health Care Rank #556 of 1015 ⚔️ RYTM vs BLTE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BLTE vs. RYTM, LGND, MANE, GRFS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Belite Bio Inc (BLTE) ranks #556 by composite RQD confidence (36/100, grade D-) and #143 by equity capitalization ($6.23B). Within this direct 5-issuer industry benchmark cohort, LGND leads on earnings valuation at 50.8x trailing P/E, while LGND leads on capital efficiency and profitability with 3.0% ROIC and — gross margin. LGND currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with BLTE at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BLTE ACTIVE
Belite Bio Inc
D- 36/100 — — -15.9% -0.69% $6.23B Benchmark Subject
RYTM
Rhythm Pharmaceuticals Inc.
D- 38/100 — 89.7% -29.6% +0.94% $6.37B /rytm-vs-blte →
LGND
Ligand Pharmaceuticals Incorporated
C 62/100 50.8x — 3.0% -4.87% $6.43B /lgnd-vs-blte →
MANE
Veradermics Incorporated
D+ 55/100 — — -11.9% -7.27% $5.84B /mane-vs-blte →
GRFS
Grifols S.A.
D+ 54/100 — — — +5.06% $5.57B /grfs-vs-blte →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001889109 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Belite Bio Inc (BLTE) reported GAAP revenue of $235.8M (+110.5% vs. FY2024 revenue of $112.0M , and +165.9% cumulative change since FY2023) , GAAP net income of -$77.6M, operating cash flow of -$37.0M, and free cash flow of -$37.1M (-26.3% YoY). On the balance sheet, BLTE closed FY2025 with $780.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $235.8M -$77.6M -$37.0M -$37.1M $780.6M —
FY2024 (FY) 2024-12-31 $112.0M -$36.1M -$29.2M -$29.4M $152.1M —
FY2023 (FY) 2023-12-31 $88.7M -$31.6M -$29.8M -$29.8M — —

3. BLTE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BLTE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Belite Bio Inc (NASDAQ: BLTE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $153.67 (-0.69% 1D, market cap $6.23B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BLTE ranks #556 in composite RQD confidence.

How does BLTE compare to RYTM and LGND in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLTE carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.9%. By comparison, RYTM (Rhythm Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.6%, cap $6.37B) and LGND (Ligand Pharmaceuticals Incorporated) posts a C grade (62/100 RQD, P/E 50.8x, ROIC 3.0%, cap $6.43B). Among the 5-stock peer group, LGND leads on earnings multiple (50.8x) while LGND leads on capital efficiency (3.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BLTE?

Per BLTE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001889109), Belite Bio Inc generated $235.8M in revenue (+110.5% YoY), -$77.6M in net income, and -$37.1M in free cash flow against $780.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BLTE trading relative to its 50-day, 200-day, and 52-week technical levels?

BLTE last traded at $153.67 (-0.69% on volume of 114,917 shares), positioning the stock -4.76% below its 50-day simple moving average ($161.35) and -4.19% below its 200-day simple moving average ($160.39). Across its 52-week range of $102.00 to $200.00, BLTE sits at the 52.7% percentile with a 14-day RSI of 50.3 (NEUTRAL RANGE) and an implied next-earnings move of ±8.5% ($140.61 to $166.73).

Direct Sub-Reports: BLTE RQD Cockpit BLTE 12M Forecast BLTE Earnings & Move BLTE Dividends & DRIP BLTE Insiders & 13F BLTE Whale Options BLTE Profit Sankey BLTE News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BLTE — Belite Bio Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Belite Bio Inc (BLTE) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $153.67 (-0.69% 1D, market capitalization $6.23B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -15.9%, gross margin of —, operating margin of —, and free cash flow yield of -0.61%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Belite Bio Inc (BLTE) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The source data identifies the company's market capitalization as $6.1B. — describes its products, customers, or revenue model. The FY 2025 reported revenue is — .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Belite Bio Inc (BLTE) reported $235.8M in annual revenue (up from $112.0M in FY2024, +110.5% YoY) and -$77.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($88.7M revenue, -$31.6M net income) through FY2025, BLTE scaled operating cash flow to -$37.0M and free cash flow to -$37.1M, backed by $780.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -0.61% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $102.00 – $200.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BLTE carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can BLTE sustain or expand its — operating margin and -15.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $235.8M and free cash flow of -$37.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BLTE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BLTE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Belite Bio Inc (BLTE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BLTE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BLTE Bull vs. Bear Conversation Board — What's Your Call at $153.67?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BLTE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BLTE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $179.50 (+16.0%)
📌 Pinned Debate

Reported cash of $352.9M in FY 2025 and a Stargardt filing in three markets give the company a potential path to a first approved treat

Picked up a starter position in BLTE in my $100K Virtual Cash book at $154.74. Reported cash of $352.9M in FY 2025 and a Stargardt filing in three markets give the company a potential path to a first approved treatment.. Trading inside a $97.99–$200.00 52-week range with -0.61% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

CapAlloc_Nerd 🐂 BULL

@CashFlowKing Agree on the RQD 36/100 quality, though with 1.0 beta I'm scaling in with half-size at $154.74 and keeping dry powder in case we test $143.91.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $117.60 (-24.0%)
Spot @ $154.74

Zero reported revenue, negative ROIC of -15.9%, negative FCF, and an insider conviction score of 3/20 leave the valuation without curre

Fading this rally in BLTE at $154.74. Zero reported revenue, negative ROIC of -15.9%, negative FCF, and an insider conviction score of 3/20 leave the valuation without current cash support.. With a beta of 1.0 and the stock sitting at $154.74 (52-wk range $97.99–$200.00), the easy multiple expansion is already priced in.

LIVE TAPE